72830-07-0

Basic information

• Product Name: 3,4-DIMETHOXY-2-METHYLPYRIDINE N-OXIDE
• Synonyms: 3,4-DIMETHOXY-2-METHYLPYRIDINE N-OXIDE;3,4-DIMETHOXY-2-MEHTYLPRIDINE N-OXIDE;2-METHYLPYRIDINE-3,4-DIMETHOXY-N-OXIDE;3,4-dimethoxy-2-methyl-1-oxidopyridin-1-ium;3,4-Dimethoxy-2-methylpyridine 1-oxide
• CAS NO: 72830-07-0
• Molecular Formula: C₈H₁₁NO₃
• Molecular Weight: 169.18
• Mol File: 72830-07-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 333.581 °C at 760 mmHg
• Flash Point: 155.545 °C
• Appearance: /
• Density: 1.119 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: 2-8°C
• PKA: 2.80±0.10(Predicted)
• CAS DataBase Reference: 3,4-DIMETHOXY-2-METHYLPYRIDINE N-OXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIMETHOXY-2-METHYLPYRIDINE N-OXIDE(72830-07-0)
• EPA Substance Registry System: 3,4-DIMETHOXY-2-METHYLPYRIDINE N-OXIDE(72830-07-0)

Safety Data

• Hazardous Substances Data: 72830-07-0(Hazardous Substances Data)

Usage

Uses

3,4-Dimethoxy-2-methylpyridine-N-oxide can be used for?one pot synthesis of 2-[2-(pyridylmethyl)thio]-1H-benzimidazoles, which are intermediates for preparing H+/K+-ATPase inhibitors. 3,4-Dimethoxy-2-methylpyridine-N-oxide is an impurity of Pantoprazole (P183000).

InChI:InChI=1/C8H11NO3/c1-6-8(12-3)7(11-2)4-5-9(6)10/h4-5H,1-3H3

Upstream product

• 67-56-1 methanol 
• 15931-25-6 3-methoxy-2-methyl-4-nitropyridine 1-oxide 
• 17184-19-9 3-hydroxy-2-methylpyrid-4-one 
• 124-41-4 sodium methylate 
• 122307-41-9 4-chloro-3-methoxy-2-methylpyridine N-oxide 
• 35392-65-5 3-methoxy-2-methylpyridine 1-oxide 
• 107512-34-5 4-Chloro-3-methoxy-2-methyl-pyridine 
• 76015-11-7 3-methoxy-2-methylpyridin-4(1H)-one 
• 4780-14-7 3-methoxy-2-methyl-4-pyrone 
• 118-71-8 Maltol 
• 107512-35-6 3,4-dimethoxy-2-methylpyridine 

Downstream Products

• 72830-08-1 2-hydroxymethyl-3,4-dimethoxypyridine 
• 102625-70-7 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole 
• 102625-64-9 pantoprazole sulfide 
• 72830-09-2 2-Chloromethyl-3,4-dimethoxy-pyridine; hydrochloride 
• 169905-10-6 2-(chloromethyl)-3,4-dimethoxypyridine 
• 102625-99-0 2-acetoxymethyl-3,4-dimethoxypyridine 

Relevant articles and documents

A pantoprazole intermediate 2 - chloromethyl - 3, 4 - dimethoxy pyridine hydrochloride preparation method

The invention belongs to the technical field of medicine, and particularly relates to a preparation method of a pantoprazole intermediate 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride. The preparation method comprises the following steps: using 3-hydroxyl-2-methyl-4-pyrone as a starting raw material, and then only performing five-step reaction to obtain the pantoprazole intermediate 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride. The preparation method reduces the reaction steps, shortens the reaction cycle, improves the working efficiency, and increases the yield coefficient.

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate

[(Pyridylmethyl)sulfinyl]benzimidazoles 1 (PSBs) are a class of highly potent antisecretory (H+,K+)-ATPase inhibitors which need to be activated by acid to form their active principle, the cyclic sulfenamide 4. Selective inhibitors of the (H+,K+)-ATPase in vivo give rise to the nonselective thiophile 4 solely at low pH, thus avoiding interaction with other thiol groups in the body. The propensity to undergo the acid-catalyzed transformation is dependent on the nucleophilic/electrophilic properties of the functional groups involved in the formation of 2 since this step is both rate-determining and pH-dependent. The aim of this study was to identify compounds with high (H+,K+)-ATPase inhibitory activity in stimulated gastric glands possessing acidic pH, but low reactivity (high chemical stability) at neutral pH as reflected by in vitro (Na+,K+)-ATPase inhibitory activity. The critical influence of substituents flanking the pyridine 4-methoxy substituent present in all derivatives was carefully studied. The introduction of a 3-methoxy group gave inhibitors possessing a combination of high potency, similar to omeprazole and lansoprazole, but increased stability. As a result of these studies, compound 1a (INN pantoprazole) was selected as a candidate drug and is currently undergoing phase III clinical studies.